Literature DB >> 24670623

Advancing the portfolio of tuberculosis diagnostics, drugs, biomarkers, and vaccines.

Alimuddin I Zumla1, Marco Schito2, Markus Maeurer3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24670623     DOI： 10.1016/S1473-3099(14)70028-3

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  12 in total

1.  "The Impact of Mycobacterium tuberculosis Immune Evasion on Protective Immunity: Implications for TB Vaccine Design" - Meeting report.

Authors:  Cesar Boggiano; Katrin Eichelberg; Lakshmi Ramachandra; Jaqueline Shea; Lalita Ramakrishnan; Samuel Behar; Joel D Ernst; Steven A Porcelli; Markus Maeurer; Hardy Kornfeld
Journal:  Vaccine       Date:  2017-05-02       Impact factor: 3.641

2.  Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries.

Authors:  L Guglielmetti; C Hewison; Z Avaliani; J Hughes; N Kiria; N Lomtadze; N Ndjeka; S Setkina; A Shabangu; W Sikhondze; A Skrahina; N Veziris; J Furin
Journal:  Int J Tuberc Lung Dis       Date:  2017-02-01       Impact factor: 2.373

Review 3.  Drug-Resistant Tuberculosis: Challenges and Progress.

Authors:  Sebastian G Kurz; Jennifer J Furin; Charles M Bark
Journal:  Infect Dis Clin North Am       Date:  2016-06       Impact factor: 5.982

4.  Drug-resistant tuberculosis clinical trials: proposed core research definitions in adults.

Authors:  J Furin; E Alirol; E Allen; K Fielding; C Merle; I Abubakar; J Andersen; G Davies; K Dheda; A Diacon; K E Dooley; G Dravnice; K Eisenach; D Everitt; D Ferstenberg; A Goolam-Mahomed; M P Grobusch; R Gupta; E Harausz; M Harrington; C R Horsburgh; C Lienhardt; D McNeeley; C D Mitnick; S Nachman; P Nahid; A J Nunn; P Phillips; C Rodriguez; S Shah; C Wells; B Thomas-Nyang'wa; P du Cros
Journal:  Int J Tuberc Lung Dis       Date:  2016-03       Impact factor: 2.373

Review 5.  Insights on recent approaches in drug discovery strategies and untapped drug targets against drug resistance.

Authors:  Ramalingam Peraman; Sathish Kumar Sure; V N Azger Dusthackeer; Naresh Babu Chilamakuru; Padmanabha Reddy Yiragamreddy; Chiranjeevi Pokuri; Vinay Kumar Kutagulla; Santhivardhan Chinni
Journal:  Futur J Pharm Sci       Date:  2021-03-03

Review 6.  Potential of immunomodulatory agents as adjunct host-directed therapies for multidrug-resistant tuberculosis.

Authors:  Alimuddin Zumla; Martin Rao; Ernest Dodoo; Markus Maeurer
Journal:  BMC Med       Date:  2016-06-15       Impact factor: 8.775

Review 7.  New anti-tuberculosis drugs and regimens: 2015 update.

Authors:  Lia D'Ambrosio; Rosella Centis; Giovanni Sotgiu; Emanuele Pontali; Antonio Spanevello; Giovanni Battista Migliori
Journal:  ERJ Open Res       Date:  2015-05-06

8.  Taking forward the World TB Day 2016 theme 'Unite to End Tuberculosis' for the WHO Africa Region.

Authors:  Francine Ntoumi; Pontiano Kaleebu; Eusebio Macete; Sayoki Mfinanga; Jeremiah Chakaya; Dorothy Yeboah-Manu; Matthew Bates; Peter Mwaba; Markus Maeurer; Eskild Petersen; Alimuddin Zumla
Journal:  Int J Infect Dis       Date:  2016-03-08       Impact factor: 3.623

9.  Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis.

Authors:  Jennifer Furin; Grania Brigden; Erica Lessem; Michael Rich; Laura Vaughan; Sharonann Lynch
Journal:  Emerg Infect Dis       Date:  2016-03       Impact factor: 6.883

10.  Temporal Expression of Peripheral Blood Leukocyte Biomarkers in a Macaca fascicularis Infection Model of Tuberculosis; Comparison with Human Datasets and Analysis with Parametric/Non-parametric Tools for Improved Diagnostic Biomarker Identification.

Authors:  Sajid Javed; Leanne Marsay; Alice Wareham; Kuiama S Lewandowski; Ann Williams; Michael J Dennis; Sally Sharpe; Richard Vipond; Nigel Silman; Graham Ball; Karen E Kempsell
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.